Doctor profile · Federal record
Dr. David Sikes, MD
Rheumatology Physician · Zephyrhills, FL
- NPI 1710098215
- 20 yrs on file
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
38051 Market Sq
Zephyrhills, FL 335427504
(813) 782-1234
fax (813) 782-4458 - Mailing address
-
38135 Market Square
Zephyrhills, FL 33542
Credentials & registration
- NPI registered
- August 2006 — 20 yrs on file
- Profile last updated
- August 27, 2021
- Specialty taxonomy
- 207RR0500X — NUCC code
- State license (1)
- Florida #ME40664
- Medicaid
- FL #067838400
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1710098215. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
163,427
Distinct HCPCS
10
Medicare allowed
$2,824,913
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J3262 |
Injection, tocilizumab, 1 mg | 61,755 | 20 | $6 | |
J1602 |
Injection, golimumab, 1 mg, for intravenous use | 27,910 | 42 | $13 | |
J3111 |
Injection, romosozumab-aqqg, 1 mg | 16,170 | 39 | $10 | |
J0717 |
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 15,200 | 13 | $5 | |
J0897 |
Injection, denosumab, 1 mg | 14,520 | 174 | $23 | |
J0129 |
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 9,825 | 23 | $42 | |
J1745 |
Injection, infliximab, excludes biosimilar, 10 mg | 5,360 | 35 | $33 | |
J9312 |
Injection, rituximab, 10 mg | 4,200 | 24 | $80 | |
Q5119 |
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,700 | 23 | $24 | |
J0517 |
Injection, benralizumab, 1 mg | 1,380 | 16 | $166 |
In context: peer comparison
Among 4 peers in Zephyrhills Rheumatology Physician, average services per provider: 5,697. This provider delivers 29× the peer median.Open Payments
Industry payments received
All-time total
$2,168
Transactions
85
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Abbvie INC. | 15 | $368.12 | |
| Janssen Biotech, INC. | 10 | $308.72 | |
| Ucb, INC. | 12 | $307.08 | |
| Amgen INC. | 12 | $298.00 | |
| Novartis Pharmaceuticals Corporation | 9 | $195.73 | |
| Pfizer INC. | 8 | $167.54 | |
| AstraZeneca Pharmaceuticals Lp | 3 | $68.00 | |
| Fresenius Kabi USA, LLC | 3 | $59.56 | |
| Lilly USA, LLC | 3 | $57.01 | |
| Kyowa Kirin, INC. | 2 | $47.53 | |
| Sobi, INC | 1 | $44.18 | |
| United Therapeutics Corporation | 2 | $40.48 | |
| Organon LLC | 2 | $38.44 | |
| Genentech USA, INC. | 2 | $36.29 | |
| Genzyme Corporation | 1 | $31.46 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,829
Patients
582
Total drug cost
$372,384
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Tramadol Hcl | Generic | 581 | 112 | $8,445 |
| Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen) | Brand | 263 | 38 | $8,146 |
| Prednisone | Generic | 193 | 103 | $2,861 |
| Methotrexate (Methotrexate Sodium) | Brand | 191 | 109 | $6,259 |
| Hydroxychloroquine Sulfate | Generic | 97 | 40 | $6,144 |
| Oxycodone-Acetaminophen (Oxycodone Hcl/Acetaminophen) | Brand | 82 | 13 | $2,308 |
| Pregabalin | Generic | 81 | 22 | $3,528 |
| Duloxetine Hcl | Generic | 64 | 30 | $973 |
| Leflunomide | Generic | 54 | 27 | $3,024 |
| Allopurinol | Generic | 52 | 22 | $1,052 |
Frequently asked questions
What is Dr. David Sikes's medical specialty?
Dr. David Sikes practices Rheumatology Physician in Zephyrhills, FL.
Where does Dr. David Sikes practice?
Dr. David Sikes practices at 38051 Market Sq, Zephyrhills, FL 335427504. Office phone: 8137821234.
What is Dr. David Sikes's NPI?
Dr. David Sikes's National Provider Identifier (NPI) is 1710098215, issued by NPPES.
What procedures does Dr. David Sikes commonly perform?
Top Medicare-reported procedures in 2023: Injection, tocilizumab, 1 mg (HCPCS J3262); Injection, golimumab, 1 mg, for intravenous use (HCPCS J1602); Injection, romosozumab-aqqg, 1 mg (HCPCS J3111). Source: CMS Medicare Physician & Other Practitioners file.